EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB
Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
... The oncologist we saw today was extremely pleased with the results telling us that he had never seen such a positive response after only two rounds of Yondelis. We'll take it!